Last reviewed 2026-04-20 · How we verify

OZOGAMICIN

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: HEPATOTOXICITY Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor frequently for signs and symptoms of VOD after treatment with MYLOTARG. ( 5.1 and 6.1 ) WARNING: HEPATOTOXICITY See full prescribing information for complete boxed warning. Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use of MYLOTARG. ( 5.1 , 6.1 )

Common side effects

• Thrombocytopenia
• Infection
• Neutropenia
• Anemia
• Leukopenia
• Fatigue
• Hemorrhage
• Pyrexia
• Nausea
• Headache
• Febrile Neutropenia
• Transaminases Increased

Serious adverse events

• Veno-Occlusive Disease (VOD)
• Infection
• Febrile Neutropenia
• Hemorrhage
• Abdominal Pain
• Pyrexia
• Fatigue

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• OZOGAMICIN CI brief — competitive landscape report
• OZOGAMICIN updates RSS · CI watch RSS